TOPEKA, Kan. (WIBW) – Stormont Vail has been participating in clinical trials for new COVID treatments since the start of the pandemic. In fact …, TOPEKA, Kan. (WIBW) – Stormont Vail has been participating in clinical trials for new COVID treatments since the start of the pandemic. In fact …, Read More
INDIANAPOLIS — The Indiana State Department of Health (ISDH) reported 3,477 more positive coronavirus cases and announced 142 additional …Read More
Dr. Christian Furman, a physician with UofL Health, talked about fighting off the coronavirus at home. (Source: UofL Health). LOUISVILLE, Ky. (WAVE) …Read More
KNOXVILLE, Tenn. — For Cynthia Finch, signing up for a vaccine trial just felt like the right thing to do. She’s a clinician, community advocate and …, KNOXVILLE, Tenn. — For Cynthia Finch, signing up for a vaccine trial just felt like the right thing to do. She’s a clinician, community advocate and …, Read More
A single global Phase III clinical trial evaluating two doses of lanifibranor (800mg and 1200mg once daily) versus placebo is intended to support U.S. New Drug Application (NDA) / EU …, A single global Phase III clinical trial evaluating two doses of lanifibranor (800mg and 1200mg once daily) versus placebo is intended to support U.S. …
Inventiva announces design of Phase III clinical trial with lanifibranor in NASH, Read More »
A single global Phase III clinical trial evaluating two doses of lanifibranor (800mg and 1200mg once daily) versus placebo is intended to support U.S. New Drug Application (NDA) / EU …, A single global Phase III clinical trial evaluating two doses of lanifibranor (800mg and 1200mg once daily) versus placebo is intended to support U.S. …
Inventiva announces design of Phase III clinical trial with lanifibranor in NASH, Read More »
A single global Phase III clinical trial evaluating two doses of lanifibranor (800mg and 1200mg once daily) versus placebo is intended to support U.S. New Drug Application (NDA) / EU …, A single global Phase III clinical trial evaluating two doses of lanifibranor (800mg and 1200mg once daily) versus placebo is intended to support U.S. …
Inventiva announces design of Phase III clinical trial with lanifibranor in NASH, Read More »
New mutations to the coronavirus that causes COVID-19 are emerging, … RNA viruses, such as coronaviruses, have incredibly dynamic genomes.Read More
Last week, a coronavirus cluster was found at a different heya involving about a dozen wrestlers and support personnel, and a referee also tested …Read More
Despite growing vaccine access, January is looking grim around the globe as the coronavirus resurges and reshapes itself from Britain to Japan to …Read More
